Newcastle-based radiation and bio-technology development company Kromek has received a new biosecurity award from the UK Ministry of Defence (UK MoD) as well as other orders in the CBRN Detection segment worth £860,000.
The firm has received a contract from the UK MoD’s Defence Science and Technology Laboratory, one of the principal government organisations dedicated to science and technology in the defence and security field, to develop novel methods of enhancing the detection of biological agents and incidents.
It has been awarded £250,000 for the 18-month project, which is being funded through the UK Government’s Defence and Security Accelerator.
This complements Kromek’s existing multi-year contracts for the development of biological-threat detection systems with a UK Government department and with the US Department of Homeland Security.
The listed firm has also received several orders from global customers in the nuclear security segment, including one totalling $470,000 for its D5 detectors under a pre-existing Indefinite Delivery, Indefinite Quantity (IDIQ) contract.
This contract was announced in April 2024 and, to date, the group has received orders of $1.9m under this IDIQ with up to $1.0m remaining to be ordered before the programme’s expiry.
The business has received three orders, totalling £252k, for its D3M detectors from distributors for end customers in Japan, Canada and Bulgaria.
“These latest CBRN detection orders from both public and private sector customers across the UK, US, Japan, Canada and Bulgaria underscore the global demand for our mission-critical solutions and the broad, growing base of organisations that rely on our technology,” said Arnab Basu, CEO of Kromek.
“We are especially proud to have been awarded a new biosecurity contract by the UK Ministry of Defence, expanding our existing collaboration in nuclear security and reinforcing our position as a trusted partner in national defence. These orders provide increased visibility on our future revenue and reflect the strong momentum building in this segment.
“We look forward to reporting further progress as we continue to scale and deliver on our strategy.”